Literature DB >> 27276655

Inverse Association Between Atopy and Melanoma: A Case-control Study.

Vivien Marasigan1, Marie-Anne Morren, Julien Lambert, Karen Medaer, Steffen Fieuws, Tamar Nijsten, Marjan Garmyn.   

Abstract

Heightened cutaneous immune surveillance in atopic patients may inhibit development of melanoma. The aim of this study was to analyse the association between atopy and melanoma (development and outcome). A total of 188 cases of melanoma and 596 healthy controls were interviewed by telephone with a standardized questionnaire on atopic, demographic and melanoma characteristics. Cases were matched with controls on important confounders (age, sex, sunburn sensitivity, hair colour, number of moles, sunburn as juvenile, ever solarium, familial melanoma). Melanoma outcome data (disease relapse and death) within cases were retrieved. Analysis showed a general inverse association between atopy and melanoma development, but this was statistically significant only for a history of personal atopy (odds ratio 0.53, 95% confidence interval: 0.30-0.96, p-value = 0.04). Among melanoma patients, atopy did not affect survival or progression. In conclusion, this study suggests an inverse association between a history of atopy and melanoma development, but not with disease progression.

Entities:  

Mesh:

Year:  2017        PMID: 27276655     DOI: 10.2340/00015555-2476

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  2 in total

1.  Noncutaneous and Cutaneous Cancer Risk in Patients With Atopic Dermatitis: A Systematic Review and Meta-analysis.

Authors:  Lily Wang; Rachel Bierbrier; Aaron M Drucker; An-Wen Chan
Journal:  JAMA Dermatol       Date:  2020-02-01       Impact factor: 10.282

2.  Atopic Dermatitis and Skin Cancer Risk: A Systematic Review.

Authors:  Yun Zhu; Hongmei Wang; Juan He; Luhui Yang; Xiaoyan Zhou; Zhe Li; Huiling Zhou; Huadi Zhao; Yuye Li
Journal:  Dermatol Ther (Heidelb)       Date:  2022-04-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.